Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Expert Opin Pharmacother. 2020 Apr 15;21(11):1319–1328. doi: 10.1080/14656566.2020.1748599

Table 3.

Barriers to utilization of antiobesity drugs

Health Care Providers
 • Negative perceptions of safety and efficacy
 • Negative USPSTF clinical recommendations
 • Desire to use least invasive options first (i.e. behavioral interventions)
 • Patient costs and ability to afford the drugs
 • Gaps in knowledge and limited experience
Patients
 • Lack of insurance coverage
 • Out of pocket costs
 • Potential for adverse effects
 • Unrealistic expectations for efficacy and rapidity of benefit